Tech Company Financing Transactions
Cardiovascular Systems Funding Round
On 9/8/2005, Cardiovascular Systems received $62.5 million in Series D funding from HealthCare Ventures, MDS Capital and Duquesne Capital Management.
Transaction Overview
Company Name
Announced On
9/8/2005
Transaction Type
Venture Equity
Amount
$62,500,000
Round
Series D
Investors
HealthCare Ventures (Lead Investor) (Henry Wendt)
MDS Capital (Lead Investor)
Proceeds Purpose
The proceeds from this offering are expected to carry us through the launch of faropenem for respiratory tract infections and will also allow us to move REP8839, a topical antibiotic being developed to treat infections caused by antibiotic-resistant bacteria such as MRSA, into clinical trials.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
1225 Old Hwy. 8 Northwest
St. Paul, MN 55112
USA
St. Paul, MN 55112
USA
Phone
Website
Email Address
Overview
Cardiovascular Systems is devoted to developing & commercializing innovative solutions for treating peripheral & coronary vascular disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Ward
VP - Bus. Development
David Whitescarver
VP - General Counsel
Alex Rosenstein
VP - Manufacturing
John Hastings
VP - Regulatory Affairs
Ryan Egeland
Browse more venture capital transactions:
Prev: 9/8/2005: Amicus Therapeutics venture capital transaction
Next: 9/8/2005: Power Paper venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs